Abstract
Background
Subdiaphragmatic paraganglioma is a rare neuroendocrine tumor for which scarce data exist regarding long-term patient outcome following resection. The aim of this study was to determine the association of surgical resection with survival.
Methods
A retrospective study at a tertiary care center was performed. Demographics, genetics, histology, and operative details were reviewed. Patients were grouped according to margin status (R0, R1, or R2) and survival calculated.
Results
A total of 50 patients with subdiaphragmatic paragangliomas underwent primary resection from 1999 to 2012. Median age at operation was 46 years, with a median tumor size of 6.0 cm. Of these patients, 30 (60 %) had a R0 resection, 11 (22 %) had a R1 resection, and 9 (18 %) had a R2 resection. There was no operative mortality, and 17 (34 %) patients had metastatic disease. Six (12 %) patients died, four (8 %) of whom had metastatic disease. Univariate analysis identified that age >50 years (p = 0.02) and undergoing a R2 resection (p = 0.03) were associated with a shorter overall survival (OS). Those with metastases at some point after their initial diagnosis had a shorter disease-free survival (DFS) than those without metastases (p = 0.04). Of 27 patients tested, 12 (44 %) had a germline succinyl dehydrogenase B (SDHB) mutation. SDHB immunohistochemistry identified 18 patients (of 27 who underwent staining) who had loss of SDHB expression in which 7 of 11 patients (63 %) who underwent genetic testing had a genetic mutation.
Conclusions
Surgical resection of subdiaphragmatic paraganglioma is safe. Survival was longest in patients who were younger, with no metastases, or had a R0 or R1 resection. Patients who test negative for a germline mutation should undergo SDHB immunostaining to identify potential hereditary carriers missed by current genetic testing.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Joynt KE, Moslehi JJ, Baughman KL (2009) Paragangliomas: etiology, presentation, and management. Cardiol Rev 17(4):159–164
Laird AM et al (2012) Paraganglioma: not just an extra-adrenal pheochromocytoma. Langenbeck’s Arch Surg 397(2):247–253
Lee JA, Duh QY (2008) Sporadic paraganglioma. World J Surg 32(5):683–687. doi:10.1007/s00268-007-9360-4
Chen H et al (2010) The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 39(6):775–783
DeLellis RA (2004) Pathology and genetics of tumours of endocrine organs. World Health Organization classification of tumours. IARC Press, Lyon, p 320
Ayala-Ramirez M et al (2011) Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab 96(3):717–725
Fishbein L et al (2013) Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing. Ann Surg Oncol 20(5):1444–1450
Welander J, Soderkvist P, Gimm O (2011) Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocr Relat Cancer 18(6):R253–R276
Schlisio S et al (2008) The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev 22(7):884–893
Yeh IT et al (2008) A germline mutation of the KIF1B beta gene on 1p36 in a family with neural and nonneural tumors. Hum Genet 124(3):279–285
Neumann HP et al (2002) Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346(19):1459–1466
Neumann HP et al (2004) Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292(8):943–951
Pasini B et al (2008) Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet 16(1):79–88
Young WF Jr (2010) Endocrine hypertension: then and now. Endocr Pract 16(5):888–902
van Nederveen FH et al (2009) An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol 10(8):764–771
Korpershoek E et al (2011) SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J Clin Endocrinol Metab 96(9):E1472–E1476
Ayala-Ramirez M et al (2013) Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma. J Clin Endocrinol Metab 98(4):1492–1497
Erickson D et al (2001) Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab 86(11):5210–5216
Oltmann SC, Chen H (2013) Doing away with the rule of 10%. Ann Surg Oncol 20(5):1403–1404
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Abadin, S.S., Ayala-Ramirez, M., Jimenez, C. et al. Impact of Surgical Resection for Subdiaphragmatic Paragangliomas. World J Surg 38, 733–741 (2014). https://doi.org/10.1007/s00268-013-2443-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00268-013-2443-5